Key Highlights
- CMS posted preliminary 2027 clinical laboratory rates on September 21, 2026, with final rates expected in November.
- The industry association says almost 1,200 tests face lower payments, and 775 of them face the maximum 15% cut in 2027.
- CMS estimates the adjustments would save about $1 billion annually and says Medicare pays roughly 16% more than private insurers for lab services.
- CareDx shares fell 15.6% on March 3, 2023, after a coverage article narrowed Medicare payment for its tests.
- Quest Diagnostics said roughly 11% of its 2025 revenue came from CMS reimbursement.
Medicare Lab Rates: Why Did Diagnostics Stocks Drop After the September 21 Proposal?
Diagnostics stocks react sharply because Medicare is a price-setter, and a single payment decision changes revenue per test for every sample billed to it. On Monday, September 21, 2026, CMS posted preliminary 2027 rates under the clinical laboratory fee schedule. The next day Quest Diagnostics (NYSE:DGX) fell 5.1% in morning trading, and Labcorp (NYSE:LH) fell more than 3%.
Quest said roughly 11% of its 2025 revenue came from CMS reimbursement. That is a modest share for a large operator, which helps explain why its move was in the single digits.
PAMA and the 15% Cap: How Do the 2027 Cuts Work?
Congress passed the Protecting Access to Medicare Act in 2014, requiring CMS to reset Medicare lab rates using what private insurers pay. The law has already produced three years of cuts of up to 10%, followed by six years of freezes. Three more years of cuts of up to 15% begin in 2027 and run through 2029.
CMS found that Medicare pays about 16% more in total for lab services than private payers do. It estimates the adjustments would save about $1 billion a year. The American Clinical Laboratory Association argues the new rates rely on data from only 2% of the labs paid under Medicare Part B in 2024, which it calls a distorted and incomplete picture.
The 15% annual limit is a ceiling, not a forecast for every test, and CMS plans to phase in the reductions. The final 2027 rates are expected in November.
Coverage Rulings: Why Did CareDx Fall 15.6% on One Article?
Smaller diagnostics companies face an additional channel, coverage determinations by Medicare contractors, which can decide whether a test is paid at all. On March 3, 2023, CareDx (NASDAQ:CDNA) fell 15.6% from about $9 after a billing article from the MolDX program narrowed Medicare coverage for its transplant surveillance tests. Raymond James estimated that 30% of CareDx's revenue was at risk, a research firm's estimate and not a company figure.
The concentration is the point. A company built around a few tests, paid largely by one government payer, has little to offset a change. Its shares can move by double digits on a document a large operator might treat as an operating detail.
Reimbursement Overhang: What Can Still Change for Diagnostics Names?
The coverage saga shows how long uncertainty can last. A proposed MolDX policy covering donor-DNA tests was issued in 2024 and retired without being finalized, and a heavily revised version arrived in summer 2025 with a 45-day comment period. As of January 2026, a final policy was still awaited, and Natera (NASDAQ:NTRA) is covered by the same policy.
Next, watch the November final rates, the comment process around the proposal, and any legislative action on the data used to set PAMA prices.






Please wait processing your request...